Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Haematopoietic stem cell transplantation for sickle cell disease – current practice and new approaches
source: British Journal of Haematology
year: 2016
authors: Arnold SD, Bhatia M, Horan J, Krishnamurti L
summary/abstract:Sickle cell disease is an inherited disorder that affects over 5 million people worldwide. Current maintenance therapy has been successful in reducing complications and enhancing life expectancy; yet subclinical complications persist. To date, allogeneic haematopoietic stem cell transplant (HSCT) remains the only available curative therapy for sickle cell disease. With declining incidences of rejection and transplant- related mortality, disease-free survival after human leucocyte antigen-identical sibling transplant exceeds 90%. However, the majority of individuals with sickle cell disease do not have an human leucocyte antigen (HLA)-identical sibling; therefore, research is expanding to focus on new approaches to alternative donor transplant. Advances in supportive care and conditioning regimens have led to expansion of the pool of donors to unrelated donors and haploidentical donors. Challenges remain in improving the safety and efficacy of HSCT from alternate donors. Early results from gene therapy may provide another curative option in patients with sickle cell disease. These approaches show early promise, but larger, longitudinal studies are needed to better determine the optimal clinical circumstances for transplant in sickle cell disease.
organization: Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta; Emory University School of Medicine, Atlanta; Columbia University Medical CenterDOI: 10.1111/bjh.14167
read more full text
Related Content
-
Researchers raise funds for phase 1 trial to test medical cannabis in sickle cell diseaseThe Sickle Cell Foundation of Georgia ...
-
MARAC Statement: Crizanlizumab (Adakveo)July 7, 2023 - SCDAA’s Medical and Res...
-
Building Capacity to Reduce Stroke in Children With Sickle Cell Anemia in the Dominican Republic: The SACRED TrialThe prevalence of sickle cell anemia (SC...
-
Management of male fertility in sickle cell disease before and after hydroxycarbamideHydroxycarbamide (hydroxyurea or HU) is ...
-
Bioverativ and Sangamo announce FDA acceptance of IND application for gene-edited cell therapy BIVV003 to treat sick...Bioverativ Inc., a Sanofi company dedi...
-
Methadone provides pain relief for kids with sickle cellMany children with sickle cell disease e...
-
Kids Who Need Sickle Cell Meds Don’t Always Get ThemLess than a fifth of U.S. children with ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.